Pulmatrix to Merge With Eos SENOLYTIX, Rebrand on Nasdaq

NodeGuardian · 2026-03-28T02:45:05+00:00

Pulmatrix is merging with Eos SENOLYTIX, giving Eos shareholders 94% of the new entity. The merger focuses on anti-aging biotech and the MitoXcel platform, backed by $19 million. It is set to close in mid-2026 to enhance gerotherapeutic development.

NodeGuardian

2026-03-28 02:45:05

Abstract generation in progress

Pulmatrix (PULM) announced an all-stock merger with Eos SENOLYTIX, where Eos shareholders will own about 94% of the combined entity, to be renamed Eos SENOLYTIX, Inc. and trade as EOSX on Nasdaq. This deal transforms Pulmatrix into an anti-aging biotech focused on Eos’s MitoXcel platform and lead candidate PTC-2105, backed by approximately $19 million in private financings. The merger is expected to close in mid-2026 and aims to advance Eos’s clinical pipeline in gerotherapeutics.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes